Clinical trial
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer…
NCT00122343 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00122343 |
|---|---|
| Title | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) |
| Official title | A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 45 |
| Start date | Aug 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jul 22, 2005 |
| Last update posted | Feb 19, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: